STAT+: Pharmalittle: We’re reading about an FDA plan for ultra-rare drugs, Novo cutting GLP-1 drug prices, and more
Stat News • 2/23/2026 – 2/24/2026
Summary
No summary yet.
Advertisement
Cluster Activity
1
1
2026-02-232026-02-24
Lindy Score Breakdown (V4.2)
7h
Age
1
Sources
from cluster
8
Hours Since Seen
Final Score11/100
CategoryAntiLindy
StatusActive
Recency Multiplier89% (0.5^8/48)
Hero EligibleYes
Story Timeline
- 2026-02-23
- 2026-02-24STAT+: Pharmalittle: We’re reading about an FDA plan for ultra-rare drugs, Novo cutting GLP-1 drug prices, and more (current)
Score BreakdownRisk 70
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: Breaking news - too recent to assess longevity
Stories gain Lindy status through source reputation, network consensus, and time survival.
Same Story from 2 sources
Breaking Similar stories
STAT+: Will Novo Nordisk’s slashing of obesity drug prices save patients’ money? It depends
Stat News • Today
STAT+: Pharmalittle: We’re reading about pharma lobbying, a disappointing Novo clinical trial, and much more
Stat News • 1 day ago
STAT+: Novo Nordisk’s next-gen obesity drug stumbles in comparison study
Stat News • 1 day ago
STAT+: Novo reports ‘triple G’ obesity drug study results
Stat News • Today
STAT+: Novo’s next-gen obesity drug stumbles in Lilly comparison study
Stat News • 1 day ago
STAT+: In earnings call, Hims CEO addresses scrutiny of GLP-1 compounding
Stat News • Today
STAT+: Drugmakers lay out their legal arguments against Trump’s drug pricing experiments
Stat News • Today
STAT+: Gossamer lung disease drug fails late-stage study, but company will still seek FDA approval
Stat News • 1 day ago
STAT+: Jeffrey Epstein’s tissue samples ignited a furor in the Harvard lab of George Church
Stat News • Today
STAT+: Pharma lobbyists focus on a surprising new target: the FDA
Stat News • 1 day ago